BioStock: New and larger shareholders back SynAct's capital raise - CEO comments

SynAct Pharma has announced a capital raise of approximately SEK 65 million. The funding, subject to approval by an extraordinary general meeting, will be achieved through a combination of directed issues and a fully guaranteed rights issue. This initiative is supported by some of the company's larger shareholders and will fund the continued development of resomelagon in rheumatoid arthritis, for which the company just received EU trial approval for its phase IIb ADVANCE study.

Read the full article at biostock.se:

https://www.biostock.se/en/2024/11/new-and-larger-shareholders-back-synacts-capital-raise-ceo-comments/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se